Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX  
10.84
+0.26 (+2.46%)
Products

FDA Grants Fast Track Designation For BioCryst's ALK-2 Inhibitor, BCX9250

Published: 06/08/2022 12:44 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - FDA Grants Fast Track Designation for Biocryst’s Alk-2 Inhibitor, Bcx9250.